An Observational Study on RoActemra/Actemra (Tocilizumab) in Clinical Practice in Patients With Rheumatoid Arthritis (TRUST)
30 aprile 2016 aggiornato da: Hoffmann-La Roche
Rheumatoid Arthritis Patients Treated With Tocilizumab in Real Clinical Practice: Effectiveness and Safety (TRUST Study)
This observational study will evaluate the efficacy and safety of RoActemra/Actemra (tocilizumab) in clinical practice in patients with moderate to severe rheumatoid arthritis.
Data will be collected from patients for the 12 months following the first infusion of RoActemra/Actemra.
Panoramica dello studio
Stato
Completato
Condizioni
Tipo di studio
Osservativo
Iscrizione (Effettivo)
322
Contatti e Sedi
Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.
Luoghi di studio
-
-
Abruzzo
-
Coppito, Abruzzo, Italia, 67100
-
Pescara, Abruzzo, Italia, 65100
-
-
Calabria
-
Reggio Calabria, Calabria, Italia, 89133
-
-
Campania
-
Avellino, Campania, Italia, 83100
-
Gragnano, Campania, Italia, 80054
-
Napoli, Campania, Italia, 80131
-
Napoli, Campania, Italia, 80138
-
Napoli, Campania, Italia, 80144
-
Salerno, Campania, Italia, 84131
-
Telese Terme, Campania, Italia, 82037
-
-
Emilia-Romagna
-
Bologna, Emilia-Romagna, Italia, 40138
-
Ferrara, Emilia-Romagna, Italia, 44100
-
Modena, Emilia-Romagna, Italia, 41100
-
Piacenza, Emilia-Romagna, Italia, 29100
-
-
Friuli-Venezia Giulia
-
Trieste, Friuli-Venezia Giulia, Italia, 34142
-
-
Lazio
-
Albano Laziale, Lazio, Italia, 00041
-
Roma, Lazio, Italia, 00168
-
Roma, Lazio, Italia, 00152
-
Roma, Lazio, Italia, 00189
-
Roma, Lazio, Italia, 00128
-
Roma, Lazio, Italia, 00145
-
Viterbo, Lazio, Italia, 01100
-
-
Liguria
-
Arenzano, Liguria, Italia, 16011
-
-
Lombardia
-
Castel Goffredo, Lombardia, Italia, 46042
-
Gavardo, Lombardia, Italia, 25085
-
Legnano, Lombardia, Italia, 20025
-
Milano, Lombardia, Italia, 20157
-
Monza, Lombardia, Italia, 20052
-
Pavia, Lombardia, Italia, 27100
-
Rozzano, Lombardia, Italia, 20089
-
Saronno, Lombardia, Italia, 21047
-
Treviglio, Lombardia, Italia, 24047
-
Vimercate, Lombardia, Italia, 20059
-
-
Marche
-
Ancona, Marche, Italia, 60020
-
Jesi, Marche, Italia, 60035
-
-
Molise
-
Agnone, Molise, Italia, 86081
-
-
Piemonte
-
Cuneo, Piemonte, Italia, 12100
-
Novara, Piemonte, Italia, 28100
-
Torino, Piemonte, Italia, 10126
-
-
Puglia
-
Brindisi, Puglia, Italia, 72100
-
Casarano (LE), Puglia, Italia, 73042
-
Foggia, Puglia, Italia, 71100
-
Martina Franca, Puglia, Italia, 74015
-
San Cesario Di Lecce, Puglia, Italia, 73016
-
-
Sardegna
-
Sassari, Sardegna, Italia, 07100
-
-
Sicilia
-
Catania, Sicilia, Italia, 95124
-
Gazzi, Sicilia, Italia, 98125
-
Palermo, Sicilia, Italia, 90127
-
Palermo, Sicilia, Italia, 90146
-
-
Toscana
-
Firenze, Toscana, Italia, 50139
-
Massa, Toscana, Italia, 54100
-
Pisa, Toscana, Italia, 56100
-
Prato, Toscana, Italia, 59100
-
-
Umbria
-
Perugia, Umbria, Italia, 06122
-
-
Veneto
-
Verona, Veneto, Italia, 37126
-
Verona, Veneto, Italia, 37134
-
-
Criteri di partecipazione
I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.
Criteri di ammissibilità
Età idonea allo studio
18 anni e precedenti (Adulto, Adulto più anziano)
Accetta volontari sani
No
Sessi ammissibili allo studio
Tutto
Metodo di campionamento
Campione di probabilità
Popolazione di studio
Patients with rheumatoid arthritis initiated on treatment with RoActemra/Actemra
Descrizione
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR) criteria
- Initiated on RoActemra/Actemra treatment according to the Summary of Product Characteristics not more than 6 months before opening of study center
Exclusion Criteria:
- Current serious infection
- Hypersensitivity to the active component or any of the excipients
- Pregnant women
Piano di studio
Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.
Come è strutturato lo studio?
Dettagli di progettazione
Coorti e interventi
Gruppo / Coorte |
|---|
|
Tocilizumab
Participants with moderate to severe Rheumatoid arthritis (RA) who had received RoActemra [Tocilizumab (TCZ)] treatment for 6 months prior to initiation of study and are inadequate responders to Disease Modifying Anti-Rheumatic Drugs (DMARDs) and anti-Tumor Necrosis Factors (anti-TNFs) agents were observed.
Participants received treatment with TCZ with dose of 8 milligrams per kilogram (mg/kg) body weight, intravenously once every 4 weeks for 12 months according to European Union (EU) approved dosage, and Summary of Product Characteristics (SmPC).
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Percentage of Participants Achieving Low Disease Activity After 6 Months of Treatment
Lasso di tempo: Up to 12 months
|
Low disease activity is defined as a disease activity score based on 28 joint count (DAS28) score lesser or equal to (</=) 3.2.
The DAS28 is an evaluation index of RA.
DAS28 applies a mathematical formula based on the following parameters: 1. Tender joints count (28 joints), 2. Swollen joints count (28 joints), 3. Erythrocyte sedimentation rate (ESR) or C reactive protein (CRP) measurement, 4. Participant's judgement on his own overall health status expressed by a visual analogue scale (VAS).
The DAS28 scale ranges from 0 to 10, where scores below 2.6 indicate best disease control, scores above 5.1 indicate worse disease control, higher scores represent higher disease activity and negative change from baseline score indicates improvement.
Percentage of participants with low disease activity was reported.
|
Up to 12 months
|
|
Percentage of Participants Achieving Disease Remission After 6 Months of Treatment
Lasso di tempo: Up to 12 months
|
Disease remission is defined as a DAS28 score < 2.6.
The DAS28 is an evaluation index of RA.
DAS28 applies a mathematical formula based on the following parameters: 1. Tender joints count (28 joints), 2. Swollen joints count (28 joints), 3. ESR or CRP measurement, 4. Participant's judgment on his own overall health status expressed by a VAS and calculates total score of 0 to approximately 10.
The DAS28 scale ranges from 0 to 10, where scores below 2.6 indicate best disease control, scores above 5.1 indicate worse disease control, higher scores represent higher disease activity and negative change from baseline score indicates improvement.
The response to therapy is defined according to the disease activity detected, compared to the previous clinical evaluation.
Percentage of participants with disease remission was reported.
|
Up to 12 months
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Mean Score of Disease Activity Based on 28 Joint Count in Participants on Monotherapy With Tocilizumab
Lasso di tempo: Baseline (Month 0), Month 1, Month 2, Month 4, Month 6, and Month 12
|
The DAS28 is an evaluation index of RA.
DAS28 applies a mathematical formula based on the following parameters: 1. Tender joints count (28 joints), 2. Swollen joints count (28 joints), 3.ESR or CRP measurement, 4. Participant's judgment on his own overall health status expressed by a VAS and calculates total score of 0 to approximately 10.
The DAS28 scale ranges from 0 to 10, where scores below 2.6 indicate best disease control, scores above 5.1 indicate worse disease control, higher scores represent higher disease activity and negative change from baseline score indicates improvement.
The response to therapy is defined according to the disease activity detected, compared to the previous clinical evaluation.
|
Baseline (Month 0), Month 1, Month 2, Month 4, Month 6, and Month 12
|
|
Mean Score of Fatigue Based on Visual Analogue Scale in Participants on Monotherapy With Tocilizumab
Lasso di tempo: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
VAS for fatigue is a 100 mm scale for participant's assessment of their current level of fatigue.
The '0 'mm corresponds to "no perception of fatigue," '100 mm' is the "maximum level of fatigue that may be perceived."
Mean score of VAS fatigue in participants were reported.
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
|
Mean Score of Health Assessment Questionnaire in Participants on Monotherapy With Tocilizumab
Lasso di tempo: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The health assessment questionnaire (HAQ) is a participant-completed questionnaire specific for RA, recommended by the American college of Rheumatology for the evaluation of quality of life.
It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities.
There are 4 possible responses for each question: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do.
To calculate HAQ, the participant must have a component set score for at least 6 of 8 component set.
The HAQ is the sum of the scores, divided by the number of component set that have a score (in range 6-8) for a total possible score of minimum/maximum i.e., 0 (best) to 3 (worst).
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
|
Number of Participants With Concomitant Medications
Lasso di tempo: Up to 12 months
|
Number of participants treated with at least one concomitant medication i.e., corticosteroid (Prednisone, Methyl prednisolone) was reported.
|
Up to 12 months
|
|
Percentage of Participants Discontinuing Treatment With Tocilizumab
Lasso di tempo: Up to 12 months
|
The percentage of participants who prematurely discontinued treatment with TCZ during the study period was reported.
|
Up to 12 months
|
|
Number of Participants With Any Adverse Events and Serious Adverse Events
Lasso di tempo: Up to 12 months
|
An adverse event (AE) was defined as any untoward medical occurrence in a participant who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment.
An AE, therefore, could be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment.
A Serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.
|
Up to 12 months
|
|
Percentage of Participants Still on Tocilizumab Treatment Till 12 Months After the 1st Infusion
Lasso di tempo: Up to 12 months
|
Percentage of participants who continued treatment till 12 months after the first infusion with TCZ was reported.
|
Up to 12 months
|
|
Number of Participants With Presence and Severity of Synovial Hyperplasia, Joint Effusion and Vascularisation of Second Metacarpo-phalangeal Joint of Right Hand.
Lasso di tempo: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The presence and severity of synovial hyperplasia (SH) and joint effusion (JE) of second metacarpo-phalangeal (MCP) joint of right hand was determined by ultrasound examination.
According to the method proposed by Naredo, synovial hyperplasia and joint effusion were evaluated based on scoring from 1 to 3 (1 = mild, 2 = moderate, 3 = marked).
Vascularization was evaluated with power doppler ultrasound and the score was assessed by a semi quantitative scale ranging from 0 to 3 (0 = normal; 1 = slight, evidence of a single flow signal; 2 = moderate, confluent vessels; 3 = marked, evidence of multiple flow signals in over half the intra articular surface).
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
|
Number of Participants With Presence and Severity of Synovial Hyperplasia, Joint Effusion and Vascularisation of Third Metacarpo-phalangeal Joint of Right Hand.
Lasso di tempo: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The presence and severity of SH and JE of third MCP joint of right hand was determined by ultrasound examination.
According to the method proposed by Naredo, SH and JE were evaluated based on scoring from 1 to 3 (1 = mild, 2 = moderate, 3 = marked).
Vascularization of third MCP joint of right hand was evaluated with power doppler ultrasound and the score was assessed by a semi quantitative scale ranging from 0 to 3 (0 = normal; 1 = slight, evidence of a single flow signal; 2 = moderate, confluent vessels; 3 = marked, evidence of multiple flow signals in over half the intraarticular surface).
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
|
Number of Participants With Presence and Severity of Synovial Hyperplasia, Joint Effusion and Vascularisation of Second Metacarpo-phalangeal Joint of Left Hand
Lasso di tempo: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The presence and severity of SH and JE of second MCP joint of left hand was determined by ultrasound examination.
According to the method proposed by Naredo, SH and JE were evaluated based on scoring from 1 to 3 (1 = mild, 2 = moderate, 3 = marked).
Vascularization of second MCP joint of left hand was evaluated with power doppler ultrasound and the score was assessed by a semi quantitative scale ranging from 0 to 3 (0 = normal; 1 = slight, evidence of a single flow signal; 2 = moderate, confluent vessels; 3 = marked, evidence of multiple flow signals in over half the intra-articular surface).
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
|
Number of Participants With Presence and Severity of Synovial Hyperplasia, Joint Effusion and Vascularisation of Third Metacarpo-phalangeal Joint of Left Hand.
Lasso di tempo: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The presence and severity of SH and JE of third MCP joint of left hand was determined by ultrasound examination.
According to the method proposed by Naredo, SH and JE were evaluated based on scoring from 1 to 3 (1 = mild, 2 = moderate, 3 = marked).
Vascularization of third MCP joint of left hand was evaluated with power doppler ultrasound and the score was assessed by a semi quantitative scale ranging from 0 to 3 (0 = normal; 1 = slight, evidence of a single flow signal; 2 = moderate, confluent vessels; 3 = marked, evidence of multiple flow signals in over half the intra-articular surface).
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
|
Mean Disease Activity Score Based on 28 Joint Count Score in the Participants With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs and Anti-Tumor Necrosis Factors Agents
Lasso di tempo: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The DAS28 index applies a mathematical formula based on the following parameters: 1. Tender joints count (28 joints), 2. Swollen joints count (28 joints) 3. ESR or CRP measurement, 4. Participant's judgment on his own overall health status expressed by a VAS and calculates total score of 0 to approximately 10.
The DAS28 scale ranges from 0 to 10, where scores below 2.6 indicate best disease control, scores above 5.1 indicate worse disease control.
The response to therapy is defined according to the disease activity detected, compared to the previous clinical evaluation.
The mean DAS28 scores were evaluated after the first infusion of TCZ in two different sub populations: participants with inadequate response (IR) to DMARD (DMARD-IR: group A) or to DMARD and anti-TNF drugs (DMARD + anti-TNF-IR: group B).
Data allowing the evaluation of DAS28 was available for 81 participants in DMARD-IR group and 203 participants in DMARD + anti-TNF-IR group.
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
|
Mean Score of Fatigue Based on Visual Analogue Scale in the Participants With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs and Anti-Tumor Necrosis Factors Agents
Lasso di tempo: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
VAS for fatigue is a 100 mm scale for participant's assessment of their current level of fatigue: 0 mm corresponds to "no perception of fatigue"; 100 mm is the "maximum that may be perceived".
The mean VAS fatigue scores were evaluated after the first infusion of TCZ in two different sub populations, classified according to the previous pharmacological treatment: participants with inadequate response to DMARD (DMARD-IR: group A) or to DMARD and anti-TNF drugs (DMARD + anti-TNF-IR: group B).
Data allowing the evaluation of fatigue (VAS) was available for 45 participants in DMARD-IR group and 113 participants in DMARD + anti-TNF-IR group.
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
|
Mean Score of Health Assessment Questionnaire in the Participants With Inadequate Response to Disease Modifying Anti-Rheumatic Drugs and Anti-Tumor Necrosis Factors Agents
Lasso di tempo: Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
The HAQ is a participant-completed questionnaire specific for RA, recommended by the American college of Rheumatology for the evaluation of quality of life.
It consists of 20 questions referring to 8 component sets: dressing/grooming, arising, eating, walking, hygiene, reach, grip and activities.
There are 4 possible responses for each question: 0 = without any difficulty, 1 = with some difficulty, 2 = with much difficulty, 3 = unable to do.
To calculate HAQ, participant must have a component set score for at least 6 of 8 component set.
The HAQ is the sum of the scores, divided by the number of component set that have a score (in range 6-8) for a total possible score minimum/maximum 0 (best) to 3 (worst).
Data allowing the evaluation of HAQ was available for 73 participants in DMARD-IR group and 157 participants in DMARD + anti-TNF-IR group.
|
Baseline, Month 1, Month 2, Month 4, Month 6, and Month 12
|
Collaboratori e investigatori
Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.
Sponsor
Studiare le date dei record
Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.
Studia le date principali
Inizio studio
1 maggio 2011
Completamento primario (Effettivo)
1 aprile 2013
Completamento dello studio (Effettivo)
1 aprile 2013
Date di iscrizione allo studio
Primo inviato
13 luglio 2011
Primo inviato che soddisfa i criteri di controllo qualità
13 luglio 2011
Primo Inserito (Stima)
14 luglio 2011
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Stima)
7 giugno 2016
Ultimo aggiornamento inviato che soddisfa i criteri QC
30 aprile 2016
Ultimo verificato
1 aprile 2016
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- ML25728
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .